We often think of the brain as a chemical soup. However, modern science proves the brain is primarily an electrical circuit.

In Episode 8 of the ReeThink Podcast, host Rudi Adigbli interviews Dr. Mai Nguyen. As the CEO and co-founder of OptoCeutics, Mai has spent seven years researching how light can stabilize our neural rhythms. Together, they explore how non-invasive neuromodulation is becoming the ultimate tool to fight cognitive decline and ADHD.

Dr. Mai Nguyen holds a PhD in Neuroendocrinology from UC Berkeley. She is a self-proclaimed “black sheep” who balances scientific rigor with “street smarts.” Mai believes that the future of neurotech belongs to the scientist-entrepreneur. Consequently, she co-founded OptoCeutics as a spin-out from DTU and UC Berkeley. Her mission is simple. She wants to translate complex neuroscience into relatable, life-changing technology.

The brain functions through specific electrical frequencies. Among these, the 40 Hertz (Gamma) frequency is critical. It controls alertness, memory, and concentration. Research indicates that Gamma rhythms often decline 20 years before Alzheimer’s symptoms appear.

Non-invasive neuromodulation acts as a “pacemaker” for these rhythms. OptoCeutics developed a patented “invisible spectral flicker” technology. This device stimulates the brain at 40Hz without the annoying strobe effect. By masking the flicker through advanced color-mixing chips, the light appears normal to the eye. Nevertheless, it reaches deep into the brain to stabilize neural signaling.

Mai argues that ADHD, anxiety, and depression are often forms of brain inflammation. When neurons “hyper-fire,” the brain becomes overstimulated and “sore,” much like an overused muscle. Non-invasive neuromodulation provides the necessary recovery phase.

Key benefits of the technology include:

• Cognitive Stabilization: Helping the brain maintain the steady rhythm needed for deep focus.

• Inflammation Reduction: Lowering the physiological stress that leads to cognitive decline.

• ADHD Support: Acting as an exogenous regulator to calm hyperactive neural signaling.

OptoCeutics employs a “Dual-Path” strategy. This approach is the gold standard for modern neurotech. First, they launched a general wellness product to capture early market data. Simultaneously, they are conducting Phase 2 clinical trials for FDA approval.

This strategy ensures that the technology remains agile. By gathering “post-market” data from thousands of users, they can refine their clinical protocols faster. Therefore, they bridge the gap between slow-moving academia and high-speed tech innovation.

At ReeWire ventures, we believe the future is focused on prevention. Mai predicts that in five years, in-home biomarkers will work alongside non-invasive neuromodulation tools. This will allow for “personalized medicine” at a massive scale. We will no longer treat diseases only after they appear. Instead, we will use light and sound to maintain a high “health span” for everyone.

ReeThink the Science. ReeWire the Rhythms.